Immunotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of randomized clinical trials
Therapeutic Advances in Medical Oncology
Published online on February 08, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Locoregionally advanced nasopharyngeal carcinoma (LANPC) is the predominant stage at diagnosis and is commonly treated with cisplatin-based chemoradiotherapy (CRT). Although this approach achieves excellent locoregional control, distant ...
Background:Locoregionally advanced nasopharyngeal carcinoma (LANPC) is the predominant stage at diagnosis and is commonly treated with cisplatin-based chemoradiotherapy (CRT). Although this approach achieves excellent locoregional control, distant ...